Amanta Healthcare Reports Q1 Revenue Of 688M Rupees, Standalone Net Profit At 33M Rupees

Market snapshot: Amanta Healthcare Limited has reported its financial results for the first quarter of FY27, showcasing steady top-line growth alongside near-term margin headwinds. Revenue rose to ₹68.8 cr, but inflationary pressures compressed operating margins, resulting in a minor decline in EBITDA and net profit.

Data Snapshot

• Revenue from operations rose to ₹68.8 cr, up ≈5.36% YoY (derived: ₹68.8 cr vs ₹65.3 cr)
• Operating EBITDA stood at ₹14.5 cr, down ≈2.68% YoY (derived: ₹14.5 cr vs ₹14.9 cr)
• EBITDA Margin contracted to 21.13%, down from 22.81% YoY
• Standalone Net Profit (PAT) declined to ₹3.3 cr, down ≈5.71% YoY (derived: ₹3.3 cr vs ₹3.5 cr)

What's Changed

• Revenue declined QoQ to ₹68.8 cr from ₹77.0 cr in Q4 FY26 (derived: ₹68.8 cr vs ₹77.0 cr)
• EBITDA declined QoQ to ₹14.5 cr from ₹16.6 cr in Q4 FY26 (derived: ₹14.5 cr vs ₹16.6 cr)
• EBITDA margin contracted marginally to 21.13% from 22% in Q4 FY26 (derived: 21.13% vs 22.00%)
• Standalone PAT decreased QoQ to ₹3.3 cr from ₹5.5 cr in Q4 FY26 (derived: ₹3.3 cr vs ₹5.5 cr)

Key Takeaways

• Amanta Healthcare maintained top-line momentum with revenue rising ≈5.36% YoY to ₹68.8 cr.
• Inflationary cost pressures and overheads during the transition phase caused a 168 bps margin contraction to 21.13%.
• The bottom-line declined to ₹3.3 cr standlone net profit, down from ₹3.5 cr in the corresponding quarter of the previous fiscal year.
• Execution of the ₹150 cr LVP and SVP capacity expansions is on schedule, with operations planned to commence in Q2 FY27.

SAHI Perspective

Amanta Healthcare is currently navigating a transitional period where revenue expansion is solid, but bottom-line and margin performance are temporarily weighed down by operational scaling and inflationary overheads. The investment thesis hinges on the successful onboarding of their expanded capacities in Q2 FY27, which are designed to double LVP capacity and significantly scale SVP capacity. Operating leverage from these lines, combined with ₹9 cr in projected annual savings from the newly commissioned 10.8 MW captive solar power project, should serve as strong structural margin drivers in the second half of the fiscal year.

Market Implications

The mixed results may lead to short-term consolidation in the stock price as the market digests the minor bottom-line compression and margin contraction. However, longer-term sentiment will likely remain positive, anchored by the high-margin profile of the SteriPort segment and the impending commissioning of the ₹150 cr capacity expansions, which should drive substantial volume-led revenue acceleration.

Trading Signals

Market Bias: Neutral

mixed performance with solid top-line growth of 5.36% offset by a minor 5.71% decline in standalone net profit and a margin contraction of 168 bps to 21.13%. Near-term momentum rests on capacity scaling.

Overweight: Pharmaceutical Formulations, Sterile Parenterals

Trigger Factors:

• Commencement and ramp-up of the expanded LVP and SVP lines in Q2 FY27
• Fluctuations in polymer and crude oil raw material prices
• Operational cost savings realized from the 10.8 MW captive solar power project

Time Horizon: Near-term (0-3 months)

Industry Context

Amanta Healthcare operates in the specialized sterile liquid parenteral sector, commanding a dominant 50–60% domestic market share in PP IV bottles under its proprietary two-port 'SteriPort' brand. This segment is characterized by high compliance standards, stringent regulatory requirements, and high capital barriers to entry, providing the company with strong defensive moats once capacity is successfully scaled.

Key Risks to Watch

• Delays in the operational ramp-up of the newly installed LVP and SVP capacity lines
• Raw material volatility, as polypropylene and LDPE container prices are highly linked to crude oil cycles
• Increased competitive intensity in the critical care and sterile injectables space

Recent Developments

Amanta Healthcare held an investor meeting on July 9, 2026, to discuss its massive ₹150 crore capacity expansion project and strategic product launches. Additionally, its 10.8 MW captive solar power plant started generating electricity at the end of Q1 FY27, which is expected to yield ₹9 crore in annual energy cost savings.

Closing Insight

Despite temporary margin compression, Amanta Healthcare remains an attractively positioned sterile liquid play. Successful execution and utilization of its newly added capacity in the upcoming quarter will be the ultimate litmus test for structural margin expansion.

High Performance Trading with SAHI.